What Is New - Pediatric Rheumatological Conditions
Take a look at our 'What is new' highlights in pediatric rheumatology!
May 2023
"The feasibility of existing JADAS10 cut-off values in clinical practice: a study of data from The Finnish Rheumatology Quality Register"
Why WIN?
The JADAS10 can be used to evaluate disease activity in clincal practice in children with JIA. Cut-offs to define uniform disease activity states across physicians have been developed, but currently different cut-off sets exist. This study shows that the cut-offs of ≤1 for clinically inactive disease, and ≤2 for low disease activity results in least misclassification, compared to active joint counts.
Do you use the (c)JADAS10 in clinical practice?
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
Link to original article: https://ped-rheum.biomedcentral.com/articles/10.1186/s12969-023-00814-x
April 2023
"Pre- and perinatal exposures associated with developing pediatric-onset immune-mediated inflammatory disease: A Danish nation-wide cohort study"
Why WIN?
Data from this nationwide Danish cohort show a high genetic burden in pediatric onset immune mediate inflammatory diseases (IMID), but also highlight potential intervenable risk factors, such as Cesarean section. This suggest a call for studies on epigenetic interactions in paediatric IMID, and increased awareness for intervenable risk factors.
Do you think we should consider the higher risk of paediatric IMIDs associated with Cesarean section in pregnant women previously diagnosed with an IMID?
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
March 2023
"Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE"
Why WINS?
Genetic heterogeneity contributes to clinical variation and inconsistent outcomes in jSLE. This study shows that in the UK, a minimum of 3.5% of jSLE patients experience genetic disease, with distinct antibody patterns and prognosis. This molecular phenotyping contribute to patient stratification and personalized treatment.
Do you think this patient group should be seen as a subvariant of jSLE?
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
February 2023
"Validity Of Ultrasonography In Detecting Enthesitis In Children: A Systematic Literature Review"
Why WINS?
Because of the peculiarities of the growing skeleton, consensual definitions and a scoring system for enthesitis in JIA are essential.
Do you routinely carry out US for enthesitis in JIA patients?
- Yes, for diagnostic purposes
- Yes, for diagnosis and follow-up
- not at all
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
Jan 2023
"Aberrant naive CD4+ T cell differentiation in systemic juvenile idiopathic arthritis is committed to B cell help"
Why WINS?
This study contributes to the understanding of sJIA pathogenesis, suggesting a role of adaptive immune cells, namely Tf/ph cells in disease, in line with the biphasic model of disease progression.
Do you think that interfering with Tf/ph polarization by interrupting IL-21 signaling could be a viable strategy in sJIA?
yes or no?
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
May 2022
" The pediatric glucocorticoid toxicity index "
Why WINS?
Glucocorticoids (GC) have wide variety of side effects and it is even more difficult to measure this in pediatric patients given that there is age impact on different toxicity profiles. There is no widely used composite measure to understand the GC toxicity in peaditric population. This study provides the development and first evaluation of pediatric GC toxicity index.
Interactive question
What will be the main purpose to use pgTI for you?
-
-
To understand steroid sparing effect of drugs in clinical trials
-
To understand the toxicity of GCs in clinical practice
-
both
-
Join the discussion on twitter... Share your response with us using the hastag #WhatIsNew and tag us @EMEUNET
May 2022
"Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA"
Why WINS?
This large analysis of real-world data, including >8000 children and young people with JIA, identified that the risk of new onset TNF inhibitor-associated psoriasis was ~5.6 times higher (adjusted for methotrexate, sex, race, family history of psoriasis, and ILAR) in those with non-psoriatic arthritis compared with those not treated with TNF inhibitors.
Interactive question
Would you be more likely to report new-onset psoriasis in JIA for those on TNFi – could this higher rate be influenced by reporting bias?
yes/no
Join the discussion on twitter... Share your response with us using the hastag #WhatIsNew and tag us @EMEUNET
December 2021
November 2021
October 2021
.jpg)
Jan 2021
December 2020
Nov 2020
October 2020
Sep 2020
February 2020
Jan 2020
December 2019
Nov 2019
Sep 2019
Aug 2019
July 2019
June 2019
May 2019
April 2019
March 2019
February 2019
Jan 2019
December 2018
Nov 2018
October 2018
Sep 2018
Click here to be directed to the article by Cann et al (2018).
Aug 2018
Childhood-onset rheumatic diseases / Bone health
Click here to be directed to the article by Inoue et al (2018).
July 2018
Juvenile localized scleroderma
Click here to be directed to the article by Agazzi et al (2018).
June 2018
Kawasaki disease
Click here to be directed to the article by Zhang et al (2018).